Back

Latest Forum Topics / QT Vascular

Post Reply

QT Vascular Going BIG Post Reply Rate topic
Kyoto2008 Elite	26-Aug-2014 19:31        Kyoto2008 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Simple, do a google on " laser angioplasty" , you can see the truth.      PTCA is old school, when laser gets into gear, PTCA will soon be a thing of the past. cleverboy      ( Date: 25-Aug-2014 23:07) Posted: Can Kyoto2008 share a bit about this laser technology that is going to overtake old school angioplasty procedures?  Kyoto2008      ( Date: 21-Aug-2014 14:34) Posted: Personally, I think this stock is pure takeover play, in the short term it' s not going to be a fantastic gainer with the subdued fundamentals.    Not forgeting that PTA and PTCA is old school angioplasty  procedures, if overtaken by laser technology the products are not going to sell for much. Too much risk to buy into this one just to wait for a takeover which may never come.
Useful To Me  Not Useful To Me
shareluck Veteran	26-Aug-2014 19:12        shareluck About Contact  Quote this Post!   Yells: "buy share also need some luck to win "
x 0   x 0  Alert Admin	issue of key patent in Japan
Useful To Me  Not Useful To Me
cleverboy Member	25-Aug-2014 23:08        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	a good and clear analysis.  agree. Sunstar      ( Date: 15-Aug-2014 16:38) Posted: Qt vascular 2QFY14 Results Note by CIMB Target S$0.73 While 1H14 headline losses (US$16.8m vs. our estimate of US13.1m) appear alarming higher than our expectation, we track QTV&rsquo s performance via its sales units, which came in above expectation. We revise our FY14 estimate due to accounting treatment of some non-recurring items but our blended valuation-based target price is intact. We reiterate our Add rating as we see QTV&rsquo s value proposition translating into a better 2H14 and rosier 2015.  Product penetration is 6x higher now  1H14 revenue is higher than that of FY13, with the Cordis distribution contract kicking in (Apr 14) QTV sold 8,321 units in 2Q14 (+368% yoy) and 13,043 units in 1H14 (+345% yoy). Importantly, 2Q14 sales were based on an agreed price under its US distribution agreement with Cordis (50% discount to previous ASP). This implies that 2Q14 revenue (US$3.2m) reflects a sixfold increase in market penetration from a year ago, when QTV employed a direct sales model. Conspicuous costs and expense items include various non-recurring items (US$4m interest on convertibles, US$3m IPO expenses) in 2Q14 and non-cash adjustments (US$2.7m) in 1H14. Stripping these out, QTV&rsquo s net losses for 2Q14 and 1H14 were c.US4m and c.US$12m, respectively.  Significantly stronger 2H14  Roll-out of the coronary Chocolate product in the US and EU in late-3Q14 (earlier than expected), larger orders in Asia and production cost-savings from technologies transfer from the US to Singapore will complement the increase in economies of scale. Note that R& D expenses will still be at around 45% of sales as the group embarks on its next wave of new product development. However, we expect the net R& D/sales ratio to come down to 35-40% on the back of more capitalisation of development costs, similar to 1H14 (US$1.6m).  Exciting time in 2015  The distribution agreements were instrumental in helping QTV lower its opex, in our view, possibly turning around its bottomline. Its new product, Silk PTA, is currently at the design feasibility stage and CE Mark submission is targeted for 1Q15. Management also said that regulatory approval in Japan for Chocolate products is expected early next year.
Useful To Me  Not Useful To Me
cleverboy Member	25-Aug-2014 23:07        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	Can Kyoto2008 share a bit about this laser technology that is going to overtake old school angioplasty procedures?  Kyoto2008      ( Date: 21-Aug-2014 14:34) Posted: Personally, I think this stock is pure takeover play, in the short term it' s not going to be a fantastic gainer with the subdued fundamentals.    Not forgeting that PTA and PTCA is old school angioplasty  procedures, if overtaken by laser technology the products are not going to sell for much. Too much risk to buy into this one just to wait for a takeover which may never come.
Useful To Me  Not Useful To Me
Kyoto2008 Elite	21-Aug-2014 14:34        Kyoto2008 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Personally, I think this stock is pure takeover play, in the short term it' s not going to be a fantastic gainer with the subdued fundamentals.    Not forgeting that PTA and PTCA is old school angioplasty  procedures, if overtaken by laser technology the products are not going to sell for much. Too much risk to buy into this one just to wait for a takeover which may never come.
Useful To Me  Not Useful To Me
moron101 Supreme	21-Aug-2014 14:27        moron101 About Contact  Quote this Post!
x 0   x 0  Alert Admin	This one is overbought. May see profit taking soon. Below 48 cts will be good bargain.
Useful To Me  Not Useful To Me
Sunstar Senior	15-Aug-2014 16:38        Sunstar About Contact  Quote this Post!
x 0   x 0  Alert Admin	Qt vascular 2QFY14 Results Note by CIMB Target S$0.73 While 1H14 headline losses (US$16.8m vs. our estimate of US13.1m) appear alarming higher than our expectation, we track QTV&rsquo s performance via its sales units, which came in above expectation. We revise our FY14 estimate due to accounting treatment of some non-recurring items but our blended valuation-based target price is intact. We reiterate our Add rating as we see QTV&rsquo s value proposition translating into a better 2H14 and rosier 2015.  Product penetration is 6x higher now  1H14 revenue is higher than that of FY13, with the Cordis distribution contract kicking in (Apr 14) QTV sold 8,321 units in 2Q14 (+368% yoy) and 13,043 units in 1H14 (+345% yoy). Importantly, 2Q14 sales were based on an agreed price under its US distribution agreement with Cordis (50% discount to previous ASP). This implies that 2Q14 revenue (US$3.2m) reflects a sixfold increase in market penetration from a year ago, when QTV employed a direct sales model. Conspicuous costs and expense items include various non-recurring items (US$4m interest on convertibles, US$3m IPO expenses) in 2Q14 and non-cash adjustments (US$2.7m) in 1H14. Stripping these out, QTV&rsquo s net losses for 2Q14 and 1H14 were c.US4m and c.US$12m, respectively.  Significantly stronger 2H14  Roll-out of the coronary Chocolate product in the US and EU in late-3Q14 (earlier than expected), larger orders in Asia and production cost-savings from technologies transfer from the US to Singapore will complement the increase in economies of scale. Note that R& D expenses will still be at around 45% of sales as the group embarks on its next wave of new product development. However, we expect the net R& D/sales ratio to come down to 35-40% on the back of more capitalisation of development costs, similar to 1H14 (US$1.6m).  Exciting time in 2015  The distribution agreements were instrumental in helping QTV lower its opex, in our view, possibly turning around its bottomline. Its new product, Silk PTA, is currently at the design feasibility stage and CE Mark submission is targeted for 1Q15. Management also said that regulatory approval in Japan for Chocolate products is expected early next year.
Useful To Me  Not Useful To Me
Sunstar Senior	14-Aug-2014 23:28        Sunstar About Contact  Quote this Post!
x 0   x 0  Alert Admin	Loss is again expected. CEO eitan konstantino had emphasized before that profitability is by choice as he prefers the company to continue focusing on its R& d. What is interesting to note that units sale has jumped tremendously to 8.3k due to its distribution with j& j. Profit margin is therefore expected to go down as qt has moved away from direct sales with higher profit margin to partnering renown companies such as J& J' s cordis to penetrate into hospitals. Note that j& j end selling px to hospitals can be as much as double it' s cost from qt. Which is why qt is measured by the success of its top line sales figure than its profit or loss. The latest loss is due to r& d expenses and once off financial cost. R& d can be recapitalised back to its balance sheet as intangible asset as it garners more commercial success. It' s has already recapitalised some back as stated in its notes.
Useful To Me  Not Useful To Me
Kyoto2008 Elite	14-Aug-2014 21:09        Kyoto2008 About Contact  Quote this Post!
x 0   x 0  Alert Admin	This is really a good discussion. Question uppermost in my mind is how much would J& J pay to fold this co into it' s own, coz this is the gameplan right from the start?    $340mln? Anything more is a bonus to those who bought below 45cents. I think this depends on how innovative QT has been and continues to be.  Just depending on current products I am not sure it' s worth 340mln bucks, I suspect the money' s in PTCA and QT is swimming with sharks.      Now if they come up with something new, 340mln is small beer.      J& J must be watching with bated breath.
Useful To Me  Not Useful To Me
sheerluck Supreme	14-Aug-2014 20:22        sheerluck About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Work for your money first then let your money work for you"
x 0   x 0  Alert Admin	There are alot of S-chips that got SGX approval for listing so why would it not allow QTV listing?   Moreever it was backed up by EDB with our taxpayers money. Anyway results wise hm...lets see.... Revenue has been increasing for the last six quarters.   Its appears good but it actually came at the expense of selling a lot more units at a much low price.   8,321 units for revenue of US$3.2mil is roughly US$388 per unit.   FY13 Q2, revenue per unit is US$579.   But since QTV is a progressing company with new products and new approval, really, very little point compare same quarter last FY.   It definitely give you a better outcome which is jurassic.   More appropiriate to compare to last quarter. Q1 revenue per unit is US$602.   So why the sudden big drop in revenue per unit???   GPM dropped from FY13 Q4 of 35% to 12% last quarter to 5.6% this quarter.   All the distribution agreements are suppose to push the sale which it does but not the margin.   So are the distributors taking a bigger cut or is the market too competitive.   Could be both but  competitive  market is already mentioned as a risk in the IPO prospectus. Finance cost recorded a US$4mil increase from last quarter mainly due to expensse incurr on convertible note but should be a one-off expense. Current EV/Revenue is 25.   Typical US bio-tech EV/Revenue  is about 10.   So QTV needs to record sale of US17mil or sell 44k unit to get its  EV/Revenue down to  10.   Shouldn' t be difficult with all these distribution channels set up. Lets give it another two quarters to see how their sale perform. Not a call to do anything.
Useful To Me  Not Useful To Me
lifeisgood Supreme	14-Aug-2014 20:08        lifeisgood About Contact  Quote this Post!
x 0   x 0  Alert Admin	Botak desperate? Stocky901      ( Date: 14-Aug-2014 19:17) Posted: Don't understand why sgx allowed this kind of stock to be listed and let peoples dream on their future growth would be good. No profits since listed.. lifeisgood      ( Date: 14-Aug-2014 18:31) Posted: $3 million revenue, $13 million losses. Losses steepen from Q1.
Useful To Me  Not Useful To Me
Stocky901 Supreme	14-Aug-2014 19:17        Stocky901 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Don't understand why sgx allowed this kind of stock to be listed and let peoples dream on their future growth would be good. No profits since listed.. lifeisgood      ( Date: 14-Aug-2014 18:31) Posted: $3 million revenue, $13 million losses. Losses steepen from Q1.  Stocky901      ( Date: 14-Aug-2014 18:21) Posted: Very heavy loss of more than $13 millions. Loss is more than last quarter. . Siao liao..
Useful To Me  Not Useful To Me
lifeisgood Supreme	14-Aug-2014 18:31        lifeisgood About Contact  Quote this Post!
x 0   x 0  Alert Admin	$3 million revenue, $13 million losses. Losses steepen from Q1.  Stocky901      ( Date: 14-Aug-2014 18:21) Posted: Very heavy loss of more than $13 millions. Loss is more than last quarter. . Siao liao..
Useful To Me  Not Useful To Me
Stocky901 Supreme	14-Aug-2014 18:21        Stocky901 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Very heavy loss of more than $13 millions. Loss is more than last quarter. . Siao liao..
Useful To Me  Not Useful To Me
lifeisgood Supreme	07-Aug-2014 13:08        lifeisgood About Contact  Quote this Post!
x 0   x 0  Alert Admin	Still waiting for results announcement. But selling has been very persistent.
Useful To Me  Not Useful To Me
Sunstar Senior	25-Jul-2014 09:31        Sunstar About Contact  Quote this Post!
x 0   x 0  Alert Admin	Thanks clever boy for the link. Very insightful info.  cleverboy      ( Date: 25-Jul-2014 00:52) Posted: http://www.mddionline.com/article/what-does-johnson-johnsons-ceo-think-medtronic-covidien-merger-07-15-2014 In Johnson & Johnson&rsquo s second quarter 2014 earnings call today, one analyst asked chairman and CEO Alex Gorsky for his take on Medtronic&rsquo s $42.9 billion acquisition of Covidien last month.   Learn more about what trends are shaping the medical device industry at the  MD& M Minneapolis conference and exposition October 29&ndash 30, 2014. Gorsky&rsquo s response, in essence, was that J& J saw something like this coming a mile away and beat its competitors to the punch. &ldquo &hellip [A]s you think back to about three years ago, when we announced the Synthes acquisition&mdash I think 2.5 to 3 years&mdash part of the strategy rationale that we made at that time was that we definitely saw consolidation in the future simply because of the number of different participants you had in the market,&rdquo he said in a Seeking Alpha transcript of the call. Part of Medtronic&rsquo s motivation for acquiring Ireland-based Covidien was to build scale. Gorsky believes, for the most part, J& J already has that. &ldquo &hellip [I]f we look at ourselves today, we think we&rsquo re clearly the broadest medical device company,&rdquo he said. &ldquo We think we&rsquo re well positioned&mdash particularly when you consider areas like general surgery, like orthopedics, we have not only broad but also deep offerings that give us solid market positions across the number of different platforms.&rdquo But there is one area in which the company hasn&rsquo t achieved the breadth it might need. &ldquo We realized that in cardiovascular we&rsquo re subscale,&rdquo Gorsky said, adding that although the company&rsquo s electrophysiology business is performing well with a growth rate of 14%, cardio is an area where the company might look to make an acquisition in the future. &ldquo We&rsquo re going to continue to watch that area very close to augment potentially onto our EP business,&rdquo he said. Stay up to date on the goings-on at FDA by attending the MD& M Minneapolis conference October 29&ndash 30, 2014. &mdash Jamie Hartford, managing editor, MD+DI [email protected]
Useful To Me  Not Useful To Me
cleverboy Member	25-Jul-2014 00:52        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	http://www.mddionline.com/article/what-does-johnson-johnsons-ceo-think-medtronic-covidien-merger-07-15-2014 In Johnson & Johnson&rsquo s second quarter 2014 earnings call today, one analyst asked chairman and CEO Alex Gorsky for his take on Medtronic&rsquo s $42.9 billion acquisition of Covidien last month.   Learn more about what trends are shaping the medical device industry at the  MD& M Minneapolis conference and exposition October 29&ndash 30, 2014. Gorsky&rsquo s response, in essence, was that J& J saw something like this coming a mile away and beat its competitors to the punch. &ldquo &hellip [A]s you think back to about three years ago, when we announced the Synthes acquisition&mdash I think 2.5 to 3 years&mdash part of the strategy rationale that we made at that time was that we definitely saw consolidation in the future simply because of the number of different participants you had in the market,&rdquo he said in a Seeking Alpha transcript of the call. Part of Medtronic&rsquo s motivation for acquiring Ireland-based Covidien was to build scale. Gorsky believes, for the most part, J& J already has that. &ldquo &hellip [I]f we look at ourselves today, we think we&rsquo re clearly the broadest medical device company,&rdquo he said. &ldquo We think we&rsquo re well positioned&mdash particularly when you consider areas like general surgery, like orthopedics, we have not only broad but also deep offerings that give us solid market positions across the number of different platforms.&rdquo But there is one area in which the company hasn&rsquo t achieved the breadth it might need. &ldquo We realized that in cardiovascular we&rsquo re subscale,&rdquo Gorsky said, adding that although the company&rsquo s electrophysiology business is performing well with a growth rate of 14%, cardio is an area where the company might look to make an acquisition in the future. &ldquo We&rsquo re going to continue to watch that area very close to augment potentially onto our EP business,&rdquo he said. Stay up to date on the goings-on at FDA by attending the MD& M Minneapolis conference October 29&ndash 30, 2014. &mdash Jamie Hartford, managing editor, MD+DI [email protected]
Useful To Me  Not Useful To Me
Sunstar Senior	24-Jul-2014 23:31        Sunstar About Contact  Quote this Post!
x 0   x 0  Alert Admin	QT Vascular seeks CE Mark approval for Drug-Coated Version of Chocolate Balloon Catheter QT has been delivering on it' s promises as outlined on its prospectus. Getting FDA approval and now seeking EU approval. With CE MARK approval, it will add Europe on top of it' s current market in US(j& j), china ( shandong weigao), Japan (itochu). Sales will be improved tremendously. J& j is currently under invested in this health device segment as quoted in its recent results announcement. With recent medtronics-Covidien merger, m& a team at j& j will be under pressure. Failing to act sooner, competitors of j& j may eye qt, in the end losing more market share. Qt will be on a trajectory path once it gain traction in its sales. As much as profit matters in companies, qt is focused on doing more r& d to be a market leader. Acquisitions of such companies are valued by price to sales ratio as end market price for distributors tend to be 80-100% higher. So if qt rakes in $30mln sales, it potentially mean it' s distributors are probably making double the profit from the inventory it gets from qt. This is the valuation yardstick used by m& a teams. With prominent investors inside, I am sure they have already done their homework past it' s current loss making position.
Useful To Me  Not Useful To Me
hotokee Master	22-Jul-2014 21:07        hotokee About Contact  Quote this Post!
x 0   x 0  Alert Admin	GOOD SHOWING. UP AGAIN.
Useful To Me  Not Useful To Me
john_ric Supreme	22-Jul-2014 15:37        john_ric About Contact  Quote this Post!
x 0   x 0  Alert Admin	$0.485 up 2 cents. john_ric      ( Date: 22-Jul-2014 11:16) Posted: QT reversing ????
Useful To Me  Not Useful To Me

                                                         First   < Newer   2101-2120 of 2353   Older>   Last